



(51) International Patent Classification:

A61K 38/21 (2006.01) *C07K 14/47* (2006.01)
A61K 39/00 (2006.01) *C07K 16/00* (2006.01)
A61P 35/00 (2006.01) *C07K 19/00* (2006.01)

(21) International Application Number:

PCT/US2022/077690

(22) International Filing Date:

06 October 2022 (06.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/253,893 08 October 2021 (08.10.2021) US
 63/328,525 07 April 2022 (07.04.2022) US

(71) Applicant: CYTOMX THERAPEUTICS, INC.

[US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US).

(72) Inventors: **BEREZHNOY, Alexey Yevgenyevich**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **LA-PUYADE, Nicole G.**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **CAI, Na**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Blvd, Suite 400, South San Francisco, California 94080 (US). **WINTER, Michael B.**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **WONG, Kenneth**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **PAIDHUNGAT, Madan M.**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **DANIEL, Dylan L.**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **LE SCOLAN, Erwan**; C/O CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US).

(54) Title: ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS




FIG. 18C

(57) **Abstract:** Provided herein are methods of treating a subject by administering a combination of an activatable cytokine construct (ACC) and a PD-1/PD-L1 pathway inhibitor in which the ACC includes: a first monomer construct including an optional first peptide mask (PM1), an optional third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and a second monomer construct including an optional second peptide mask (PM2), an optional fourth cleavable moiety (CM4), a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), wherein the CM2 is positioned between the CP2 and the DD2; wherein the DD1 and the DD2 bind to each other thereby forming a dimer of the first monomer construct and the second monomer construct; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

[Continued on next page]

(74) **Agent: HARSTON, Aydin H.**; 901 New York Avenue,
NW, Suite 900 East, Washington, District of Columbia
20001 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))